• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4641089)   Today's Articles (4158)   Subscriber (50406)
For: Delgado S, Hernandez J, Tornes L, Rammohan K. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series. BMC Neurol 2021;21:48. [PMID: 33530945 DOI: 10.1186/s12883-021-02058-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Accepted: 01/13/2021] [Indexed: 01/07/2023]  Open
Number Cited by Other Article(s)
1
Hernandez J. Multiple sclerosis treatment review for primary care providers. Nurse Pract 2024;49:38-47. [PMID: 38915149 PMCID: PMC11186711 DOI: 10.1097/01.npr.0000000000000202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/26/2024]
2
Nygaard GO, Torgauten H, Skattebøl L, Høgestøl EA, Sowa P, Myhr KM, Torkildsen Ø, Celius EG. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. Mult Scler Relat Disord 2022;62:103812. [DOI: 10.1016/j.msard.2022.103812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 04/12/2022] [Accepted: 04/16/2022] [Indexed: 11/29/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA